CN1120157C - 取代的喹啉－2－甲酰胺、其制备方法和其作为药物的应用以及其中间体 - Google Patents

取代的喹啉－2－甲酰胺、其制备方法和其作为药物的应用以及其中间体 Download PDF

Info

Publication number
CN1120157C
CN1120157C CN96122806A CN96122806A CN1120157C CN 1120157 C CN1120157 C CN 1120157C CN 96122806 A CN96122806 A CN 96122806A CN 96122806 A CN96122806 A CN 96122806A CN 1120157 C CN1120157 C CN 1120157C
Authority
CN
China
Prior art keywords
formula
alkyl
compound
hydrogen
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN96122806A
Other languages
English (en)
Chinese (zh)
Other versions
CN1154365A (zh
Inventor
K·维德曼
K·H·巴伦格哈斯
G·施安克
M·比凯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FIBRE GENE Inc
Original Assignee
Hoechst AG
Fiber Genetics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19536263A external-priority patent/DE19536263A1/de
Application filed by Hoechst AG, Fiber Genetics filed Critical Hoechst AG
Publication of CN1154365A publication Critical patent/CN1154365A/zh
Application granted granted Critical
Publication of CN1120157C publication Critical patent/CN1120157C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN96122806A 1995-09-28 1996-09-26 取代的喹啉－2－甲酰胺、其制备方法和其作为药物的应用以及其中间体 Expired - Lifetime CN1120157C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19536263A DE19536263A1 (de) 1995-09-28 1995-09-28 Substituierte Chinolin-2-carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19536263.2 1995-09-28
DE19605170 1996-02-13
DE19605170.3 1996-02-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN00118801A Division CN1282737A (zh) 1995-09-28 2000-06-14 用于制备取代的喹啉－2－甲酰胺的中间体

Publications (2)

Publication Number Publication Date
CN1154365A CN1154365A (zh) 1997-07-16
CN1120157C true CN1120157C (zh) 2003-09-03

Family

ID=26019051

Family Applications (2)

Application Number Title Priority Date Filing Date
CN96122806A Expired - Lifetime CN1120157C (zh) 1995-09-28 1996-09-26 取代的喹啉－2－甲酰胺、其制备方法和其作为药物的应用以及其中间体
CN00118801A Pending CN1282737A (zh) 1995-09-28 2000-06-14 用于制备取代的喹啉－2－甲酰胺的中间体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN00118801A Pending CN1282737A (zh) 1995-09-28 2000-06-14 用于制备取代的喹啉－2－甲酰胺的中间体

Country Status (20)

Country Link
US (2) US5719164A (https=)
EP (1) EP0765871B1 (https=)
JP (1) JPH09124606A (https=)
KR (1) KR970061869A (https=)
CN (2) CN1120157C (https=)
AT (1) ATE263155T1 (https=)
AU (1) AU728208B2 (https=)
CA (1) CA2186717A1 (https=)
CZ (1) CZ283396A3 (https=)
DE (1) DE59610950D1 (https=)
ES (1) ES2215184T3 (https=)
HU (1) HUP9602685A3 (https=)
IL (2) IL135495A (https=)
MX (1) MX9604378A (https=)
MY (1) MY133647A (https=)
NO (1) NO308600B1 (https=)
NZ (1) NZ299455A (https=)
PL (1) PL316321A1 (https=)
SG (1) SG45503A1 (https=)
SI (1) SI9600287A (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US20020198145A1 (en) * 1999-06-10 2002-12-26 Cognetix, Inc. MuO-conopeptides and their use as local anesthetics
DE60122939T2 (de) * 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
JP4590157B2 (ja) * 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2005034929A2 (en) * 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
AU2006286654A1 (en) 2005-07-27 2007-03-08 F. Hoffmann-La Roche Ag 4-aryloxy quinoline derivatives as 5-HT6 modulators
EP1960363B1 (en) * 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
BRPI0707302B8 (pt) * 2006-01-27 2021-05-25 Fibrogen Inc compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
US7625927B2 (en) * 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
KR100949975B1 (ko) * 2006-03-30 2010-03-29 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
AU2007334323B2 (en) * 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US8048894B2 (en) * 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
EP2155746A2 (en) * 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
US8030346B2 (en) * 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
PT2512243E (pt) * 2009-12-17 2016-06-08 Merck Sharp & Dohme Moduladores alostéricos positivos de recetor de quinolina amida m1
EA034451B1 (ru) 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
NO2686520T3 (https=) 2011-06-06 2018-03-17
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
TWI616430B (zh) 2012-07-27 2018-03-01 百健Ｍａ公司 Ａｔｘ調節劑
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR20210108367A (ko) 2018-11-09 2021-09-02 비바체 테라퓨틱스, 인크. 비시클릭 화합물
MX2021012638A (es) 2019-04-16 2022-01-04 Vivace Therapeutics Inc Compuestos biciclicos.
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661269A1 (de) * 1993-12-30 1995-07-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1107145A (zh) * 1993-11-02 1995-08-23 赫彻斯特股份公司 取代的杂环羧酰胺、它们的制备及作为药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
EP0541042A1 (de) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK122693D0 (da) * 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
ATE149485T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107145A (zh) * 1993-11-02 1995-08-23 赫彻斯特股份公司 取代的杂环羧酰胺、它们的制备及作为药物的应用
EP0661269A1 (de) * 1993-12-30 1995-07-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
AU728208B2 (en) 2001-01-04
IL135495A (en) 2002-12-01
JPH09124606A (ja) 1997-05-13
CA2186717A1 (en) 1997-03-29
KR970061869A (ko) 1997-09-12
PL316321A1 (en) 1997-04-01
MX9604378A (es) 1997-03-29
ATE263155T1 (de) 2004-04-15
AU6583896A (en) 1997-04-10
NO964093L (no) 1997-04-01
HUP9602685A2 (hu) 1998-09-28
SI9600287A (en) 1997-04-30
HU9602685D0 (en) 1996-11-28
ES2215184T3 (es) 2004-10-01
MY133647A (en) 2007-11-30
NO964093D0 (no) 1996-09-27
NZ299455A (en) 1997-06-24
SG45503A1 (en) 1998-01-16
NO308600B1 (no) 2000-10-02
CZ283396A3 (en) 1997-04-16
HUP9602685A3 (en) 2001-04-28
EP0765871A1 (de) 1997-04-02
US5726305A (en) 1998-03-10
IL119302A0 (en) 1996-12-05
EP0765871B1 (de) 2004-03-31
CN1282737A (zh) 2001-02-07
CN1154365A (zh) 1997-07-16
US5719164A (en) 1998-02-17
DE59610950D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
CN1120157C (zh) 取代的喹啉－2－甲酰胺、其制备方法和其作为药物的应用以及其中间体
CN1304390C (zh) 新颖的γ—分泌酶抑制剂
CN1117079C (zh) 取代的异喹啉－3－甲酰胺类化合物,其制备方法及其作为药物的用途
CN1220682C (zh) 抑制因子Xa的杂环衍生物
CN1158279C (zh) 作为血管紧张肽(1-7)受体兴奋剂的1-(p-噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂
CN1036341C (zh) 咪唑衍生物的制备方法
CN1107145A (zh) 取代的杂环羧酰胺、它们的制备及作为药物的应用
CN1107144A (zh) 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途
CN1444563A (zh) 喹啉和喹唑啉衍生物
CN1207730A (zh) 喹啉衍生物
CN1894274A (zh) 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂
CN1407972A (zh) 4－嘧啶基－n－酰基－l－苯基丙氨酸类化合物
CN1294577A (zh) 钾通道抑制剂
CN1060472A (zh) 三肽抗凝血酶剂
CN1147260A (zh) 神经激肽(快速激肽)拮抗剂
CN1102648A (zh) 取代的单-和双-吡啶基甲基吡啶酮类化合物
CN1845909A (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹喔啉衍生物及它们的用途
CN1108257A (zh) 杂环上取代的苯基-环己烷羧酸衍生物
CN1639119A (zh) 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
CN1183156C (zh) 杂环化合物、其中间体和弹性蛋白酶抑制剂
CN1038640A (zh) 二环碳酰胺、其制备方法及含该物质的药物组合物
CN1058019C (zh) 环状氨基酸衍生物
CN1150189C (zh) 用作整联蛋白抑制剂的苯并吡喃酮和苯并二氢吡喃酮衍生物
CN1047084A (zh) 具有酶抑制作用的二肽衍生物
CN1194978A (zh) 苄氧基取代的稠合n杂环化合物,其制法及其作为缓激肽拮抗剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: FIBRE GENE CO.,LTD.

Free format text: FORMER OWNER: HOECHST AKTIENGESELLSCHAFT (DE)

Effective date: 20020614

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20020614

Address after: California, USA

Applicant after: Fibre Gene Inc.

Address before: Frankfurt, Federal Republic of Germany

Applicant before: Hechester JSC

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20030903

EXPY Termination of patent right or utility model